Walleye Capital
PRTK

Walleye Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Walleye Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,400
Closed -$14K – 2355
2019
Q2 		$14K Buy
+3,400
New +$16.2K ﹤0.01% 1568

Other funds holding PRTK

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Walleye Capital's PRTK Position: Q4 2022 in Review

Walleye Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 12,000 shares — an estimated $31K sold.

Walleye Capital first reported a position in PRTK in Q3 2018 and held it in 5 quarters. The position peaked at $146K in Q2 2019. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

  • Walleye Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 12,000 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $31K.
  • Walleye Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
  • Walleye Capital's Paratek Pharmaceuticals, Inc. position peaked at $146K in Q2 2019.
  • 76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.